The 'pill scare': The responses of authorities, doctors and patients using oral contraception

Human Reproduction Update

Volumn 5, Issue 6, 1999, Pages 627-632

  Szarewski, Anne ^a,b   Mansour, Diana ^c  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b Margaret Pyke Centre   (United Kingdom)

^c NATIONAL HEALTH SERVICE   (United Kingdom)

Author keywords

'Pill scare'; Oral contraception; Patient confidence; Regulatory authority; Third generation COC

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ABORTION; FEMALE; HUMAN; ORAL CONTRACEPTION; PATIENT; PHYSICIAN; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0033389530     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/5.6.627     Document Type: Review

References (59)

1. Alexandre, J.M. and Strandberg, K. (1997) EMEA and third generation oral contraceptives. Lancet, 350, 290.
2. Allison, C. and Roizon, J. (1996) The aftermath of the oral contraceptive 'scare'. Br. J. Sexual Medicine, 5-7.
3. Allison, C., Roizon, J. and Olivier, P. (1997) The 1995 Pill scare: women's perceptions of risk and sources of information. Br. J. Fam. Plann., 23, 79-82.
4. Armstrong. J.L., Reid, M. and Bigrigg, A. (1995) Effect on women attending a family planning clinic. Br. Med. J., 311, 1637.
5. Belsey, E.M. (1988) The association between vaginal bleeding pattern and reasons for discontinuation of contraceptive use. Contraception, 38, 207-225.
6. Benagiano, G. (1998) Venous thromboembolism and the pill. Learning from the past, venous thromboembolism and the pill: an endless saga. Hum. Reprod., 13, 1115-1116.
7. Bodard, S. (1997) Casualties of the 'pill alert' of October 1995 in the Bristol area. Br. J. Fam. Plann., 22, 196.
8. BPAS (1996) April 15th. Report on terminations, British Pregnancy Advisory Service, Solihull, UK.
9. Brill, K., Muller, C., Schnitker, J. and Albring, M. (1991) The influence of different modern low-dose oral contraceptives on intermenstrual bleeding. Adv. Contraception, 7 (Suppl. 2), 51-61.
10. Bromham, D.R. (1996) Another pill scare - should we audit its impact? Audit Unit News of the Faculty of Family Planning and Reproductive Health Care, 1, 2-3.
11. British National Formulary (1991) 22nd edn, p. 272.
12. Child, T.J., Rees, M. and MacKenzie, I.Z. (1996) Pregnancy terminations after oral contraception scare. Lancet, 347, 1260-1261.
13. Cohen, J. (1998) Recommendations on the safety of oral contraceptives are too important for the regulating agencies alone. Hum. Reprod., 13, 1116-1117.
14. CPMP (1996) Position statement on oral contraceptives containing desogestrel or gestodene. CPMP/374/96, 17th April.
15. Craft, N. (1995) Clots of trouble. Br. Med. J., 311, 1172-1173.
16. Crook, D. (1997) Do different brands of oral contraceptives differ in their effects on cardiovascular disease? Br. J. Obstet. Gynaecol., 104, 516-520.
17. Department of Health (1999) Oral Contraceptives - Clearer information for woman and health professionals. Press Release, 7th April.
18. Drug and Therapeutics Bulletin (1992) Starting oral contraceptives - which, when and how? Vol. 30, no. 11.
19. Edwards, R.G., Beard, H.K. and Bradshaw, J.P. (1997) Balancing risks and benefits of oral contraception (editorial). Hum. Reprod., 12, 2339-2340.
20. Egarter, C., Strohmer, H., Lehner, R. et al. (1997) Contraceptive knowledge and attitudes of Austrian adolescents after mass media reports linking third-generation oral contraceptives with an increased risk of venous thromboembolism. Contraception, 56, 147-152.
21. Erkkola, R., Hirvonen, E., Luikku, J. et al. (1990) Ovulation inhibitors containing cyproterone acetate or desogestrel in treatment of hyperandrogenic symptoms. Acta Obstet. Gynecol. Scand., 69, 61-65.
22. Ferguson, J.J. and Jenkins, M.G.V. (1996) Effect of CSM's warning about safety of third generation oral contraceptives. General practitioners in England prescribed second generation pills instead. Br. Med. J., 313, 363.
23. Gerstman, B.B., Piper, J.M., Tomita, D.K. et al. (1991) Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am. J. Epidemiol., 133, 32-37.
24. Graham, A., Grieve, F., Davie, J. and Glasier, A. (1995) Oral contraceptives and venous thromboembolism. Br. Med. J., 346, 1430.
25. Guillebaud, J. (1989) Practical prescribing of the combined oral contraceptive pill. In Filshie, M. and Guillebaud, J. (eds), Contraception Science and Practice. Butterworth-Heinemann, 1989, pp. 69-93.
26. Guillebaud, J. (1995) Advising women on which pill to take. Br. Med. J., 331, 1111-1112.
27. Guillebaud, J. (1996) The informed user is the chooser: a bulletin from the Margaret Pyke Centre. January, 1996, Margaret Pyke Centre, London.
28. Hillard, P.A. (1989) The patient's reaction to side-effects of oral contraceptives. Am. J. Obstet. Gynecol., 161, 1412-1415.
29. Hope, S. (1996) Pill consultations now take longer. GP News, March 8th, p. 21.
30. Inman, W.H.W., Vessey, M.P., Westerholm, B. and Engelund, A. (1970) Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br. Med. J., 2, 203-209.
31. International Working Group on Enhancing Patient Compliance and Oral Contraceptive Efficacy (1993) Consensus Statement. Br. J. Fam. Plann., 18, 126-129.
32. Iverson, O. and Nilsen, S.T. (1996) Abortions increased by nearly 8% in Norway. Br. Med. J., 313, 363-364.
33. Johnson, A.M., Wadsworth, J., Wellings, K. and Field, J. (1994) Sexual Attitudes and Lifestyles. Blackwell Scientific Publications, London.
34. Jick, H., Jick, S., Gurewich, V. et al. (1995) Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet, 346, 1589-1593.
35. Jordan, W.M. (1961) Pulmonary embolism. Lancet, ii, 1146-1147.
36. Killick, S. and Murty, J. (1996) An audit of emergency communication following the October 1995 pill alert in the UK. Br. J. Fam. Plann., 22, 142-144.
37. Levrier, M., Degrelle, H., Bestaux, Y. et al. (1988) Efficacité sur l'acne des contraceptifs oraux. Rev. Fr. Gynecol. Obstet., 83, 573-576.
38. Lewis, M.A., Spitzer, W.O., Heinemann, L.A.J. et al. (1997a) Lowered risk of dying of heart attack with third generation pill may offset risk of dying of thromboembolism. Br. Med. J., 515, 679-680.
39. Lewis, M.A., Heinemann, L.A.J., Spitzer, W.O. et al. (1997b) The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Contraception, 56, 129-140.
40. Loudon, N.B., Kirkman, R.J.E. and Dewsbury, J.A. (1990) A double-blind comparison of the efficacy and acceptability of Femodene and Microgynon-30. Eur. J. Obstet. Gynecol. Reprod. Biol., 34, 257-266.
41. Mango, D., Ricci, S., Manna, P. et al. (1996) Clinical and hormonal effects of ethinyloestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception, 53, 163-170.
42. Mills, A. (1997) Combined oral contraception and the risk of venous thromboembolism. Hum. Reprod., 12, 2595-2598.
43. Mills, A. and Edwards, I.R. (1999) Venous thromboembolism and the pill. The combined oral contraceptive pill - are poor communication systems responsible for loss of confidence in this contraceptive method? Hum. Reprod., 14, 7-10.
44. Office for National Statistics. Abortion statistics (1997) Legal abortions carried out under the 1967 Abortion Act in England and Wales. Series AB no. 23. The Stationary Office.
45. Redmond, G.P., Olson, W.H., Lippman, J.S. et al. (1997) Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet. Gynecol., 89, 615-622.
46. Seamark, C.J. (1995) Effect on women in a general practice in Devon. Br. Med. J., 311, 1637.
47. Skjeldestad, F.E. (1997) Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third generation oral contraceptives. Contraception, 55, 11-14.
48. Spitzer, W.O. (1998) Thromboembolism and the pill: the saga must end. Hum. Reprod., 13, 1117-1120.
49. Spitzer, W.O., Lewis, M.A., Heinemann, L.A.J. et al. on behalf of the Transnational Research Group on Oral Contraceptives and the Health of Young Women (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br. Med. J., 312, 83-88.
50. Stadel, B. V. (1981) Oral contraceptives and cardiovascular disease. N. Engl. J. Med., 305, 612-618.
51. Statement from the Clinical and Scientific Committee of the Faculty of Family Planning and Reproductive Health Care (1995) Risk of venous thromboembolism and the combined oral contraceptive pill. 15th December, 1995.
52. Szarewski, A. (1997) Third generation pill warnings were premature. Lancet, 350, 497.
53. Szarewski, A. (1998) Medico-legal fears cloud prescribing issues. In Oral Contraceptives: Results and Interpretation of a GP Survey on Attitudes and Prescribing Habits. Trends Interpreter, January 1998.
54. Szarewski, A. (1999) Revised guidelines for prescribing third generation pills (editorial). Trends Urol. Gynaecol. Sex. Health, May 1999.
55. Vessey, M.P. (1980) Female hormones and vascular disease - an epidemiological overview. Br. J. Fam. Plann., 6 (Suppl), 1-12.
56. Vessey, M.P., Mant, D., Smith, A. and Yeates, D. (1986) Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br. Med. J., 292, 526.
57. Walling, M. (1998) Uncertainty remains over use of the pill. In Oral Contraceptives: Results and Interpretation of a GP Survey on Attitudes and Prescribing Habits. Trends Interpreter, January 1998.
58. Wood, R., Botting, B. and Dunnell, K. (1997) Trends in conceptions before and after the 1995 pill scare. Population Trends, 89, 5-12.
59. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995) Effects of different progestogens in low oestrogen oral contraceptives on venous thromboembolism. Lancet, 346, 1582-1588.